Industry
Neowise Biotechnology
Total Trials
4
Recruiting
4
Active
4
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
4 recruiting
Enrollment Performance
Analytics
Phase 1
4(100.0%)
4Total
Phase 1(4)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (4)
Showing 4 of 4 trials
NCT07266298Phase 1Recruiting
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors
Role: lead
NCT06484790Phase 1Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Role: collaborator
NCT06478251Phase 1Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Role: collaborator
NCT06484556Phase 1Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Role: collaborator
All 4 trials loaded